Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
PBYI's Cash-to-Debt is ranked higher than
79% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. PBYI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
PBYI' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
PBYI's Interest Coverage is ranked higher than
73% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PBYI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PBYI' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 31.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -202.04
PBYI's ROE % is ranked lower than
89% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. PBYI: -202.04 )
Ranked among companies with meaningful ROE % only.
PBYI' s ROE % Range Over the Past 10 Years
Min: -202.04  Med: -106.94 Max: -37.64
Current: -202.04
-202.04
-37.64
ROA % -152.64
PBYI's ROA % is ranked lower than
90% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. PBYI: -152.64 )
Ranked among companies with meaningful ROA % only.
PBYI' s ROA % Range Over the Past 10 Years
Min: -1700  Med: -109.18 Max: -36.94
Current: -152.64
-1700
-36.94
ROC (Joel Greenblatt) % -5703.54
PBYI's ROC (Joel Greenblatt) % is ranked lower than
82% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. PBYI: -5703.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PBYI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10585.02  Med: -7115.5 Max: -2978.59
Current: -5703.54
-10585.02
-2978.59
3-Year EBITDA Growth Rate 63.40
PBYI's 3-Year EBITDA Growth Rate is ranked higher than
92% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. PBYI: 63.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PBYI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 29.7  Med: 301.65 Max: 882.4
Current: 63.4
29.7
882.4
3-Year EPS without NRI Growth Rate 63.40
PBYI's 3-Year EPS without NRI Growth Rate is ranked higher than
93% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. PBYI: 63.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PBYI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 58.2 Max: 883
Current: 63.4
0
883
GuruFocus has detected 4 Warning Signs with Puma Biotechnology Inc $PBYI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PBYI's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

PBYI Guru Trades in Q3 2016

Jana Partners 76,074 sh (New)
Eaton Vance Worldwide Health Sciences Fund Sold Out
Steven Cohen 1,028,706 sh (-27.34%)
John Paulson 84,500 sh (-42.04%)
» More
Q4 2016

PBYI Guru Trades in Q4 2016

Jana Partners 142,727 sh (+87.62%)
Steven Cohen Sold Out
John Paulson 15,690 sh (-81.43%)
» More
Q1 2017

PBYI Guru Trades in Q1 2017

Jim Simons 206,500 sh (New)
John Paulson 15,690 sh (unchged)
Jana Partners Sold Out
» More
Q2 2017

PBYI Guru Trades in Q2 2017

Steven Cohen 131,900 sh (New)
John Paulson 27,500 sh (+75.27%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PBYI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-06-30 Add 75.27%0.01%$29 - $88.85 $ 104.5088%27,500
John Paulson 2016-12-31 Reduce -81.43%0.05%$30.55 - $65.63 $ 104.50142%15,690
John Paulson 2016-09-30 Reduce -42.04%0.02%$28.54 - $70.41 $ 104.50107%84,500
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CLVS, NAS:FGEN, NAS:NKTR, NAS:TECH, NAS:AGIO, NAS:ACAD, NAS:PTLA, NAS:ONCE, NAS:JUNO, NAS:AVXS, NAS:SRPT, NAS:LGND, NAS:UTHR, NAS:LOXO, NAS:NBIX, NAS:BPMC, NAS:FOLD, NAS:HALO, NAS:SAGE, NYSE:XON » details
Traded in other countries:0PB.Germany,
Headquarter Location:USA
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology is a biotechnology company focused on developing novel therapeutics for the treatment of cancer. Puma licenses the commercial rights to its current drug candidates. The company expects to augment its product pipeline by acquiring, through license or otherwise, additional drug candidates for research and development and potential commercialization. In evaluating potential drug candidates, Puma employs disciplined decision criteria favoring drug candidates that have undergone at least some clinical study.

Top Ranked Articles about Puma Biotechnology Inc

PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. - PBYI
PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm
Options trade reports for BlackBerry, The Blackstone Group, MOMO Inc., Oracle Corporation and Puma Biotechnology include trade ideas that offer returns of 21% or more!
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Puma Biotechnology, Inc.
The Klein Law Firm Announces a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017 (PBYI)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI
PBYI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 – PBYI
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Puma Biotechnology, Inc. (Nasdaq: PBYI) To Contact Brower Piven Before The Lead Plaintiff Deadline

Ratios

vs
industry
vs
history
PB Ratio 32.24
PBYI's PB Ratio is ranked lower than
93% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. PBYI: 32.24 )
Ranked among companies with meaningful PB Ratio only.
PBYI' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 33.55
Current: 32.24
0
33.55
EV-to-EBIT -12.87
PBYI's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. PBYI: -12.87 )
Ranked among companies with meaningful EV-to-EBIT only.
PBYI' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.42  Med: 0 Max: 0
Current: -12.87
-13.42
0
EV-to-EBITDA -12.93
PBYI's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. PBYI: -12.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
PBYI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.49  Med: 0 Max: 0
Current: -12.93
-13.49
0
Current Ratio 3.40
PBYI's Current Ratio is ranked higher than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. PBYI: 3.40 )
Ranked among companies with meaningful Current Ratio only.
PBYI' s Current Ratio Range Over the Past 10 Years
Min: 0.67  Med: 5.4 Max: 91.42
Current: 3.4
0.67
91.42
Quick Ratio 3.40
PBYI's Quick Ratio is ranked higher than
56% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. PBYI: 3.40 )
Ranked among companies with meaningful Quick Ratio only.
PBYI' s Quick Ratio Range Over the Past 10 Years
Min: 0.67  Med: 5.4 Max: 91.42
Current: 3.4
0.67
91.42

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.30
PBYI's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. PBYI: -8.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PBYI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -112.2  Med: -47.6 Max: -4.2
Current: -8.3
-112.2
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 39.13
PBYI's Price-to-Net-Cash is ranked lower than
80% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. PBYI: 39.13 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PBYI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.69  Med: 14.69 Max: 60.47
Current: 39.13
4.69
60.47
Price-to-Net-Current-Asset-Value 35.79
PBYI's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. PBYI: 35.79 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PBYI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.26  Med: 13.42 Max: 55.83
Current: 35.79
4.26
55.83
Price-to-Tangible-Book 32.24
PBYI's Price-to-Tangible-Book is ranked lower than
89% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. PBYI: 32.24 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PBYI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.17  Med: 12.36 Max: 50.75
Current: 32.24
4.17
50.75
Earnings Yield (Greenblatt) % -7.77
PBYI's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. PBYI: -7.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PBYI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1114.41  Med: 0 Max: 0
Current: -7.77
-1114.41
0

More Statistics

EPS (TTM) $ -8.12
Beta2.13
Short Percentage of Float25.09%
52-Week Range $28.35 - 109.85
Shares Outstanding (Mil)37.21

Analyst Estimate

Dec17 Dec19
Revenue (Mil $) 52 607
EPS ($) -7.07 2.81
EPS without NRI ($) -7.07 2.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}